Literature DB >> 7248957

Salvage of circulating pyrimidine nucleosides in the rat.

J D Moyer, J T Oliver, R E Handschumacher.   

Abstract

A new procedure was developed to measure uridine and cytidine in plasma. These nucleosides are present in micromolar concentrations in the plasma of rats, mice, and humans. Inhibitors of pyrimidine synthesis de novo (pyrazofurin or N-phosphonacetyl-L-aspartate) produce only modest decreases in the concentration of circulating uridine or cytidine in the rat. Since both uridine and cytidine are rapidly cleared from the circulation of the rat, constant infusions of radiolabeled uridine and cytidine were used to establish a steady-state specific activity of circulating nucleoside without altering the normal endogenous concentration. These studies permitted an estimation of the contribution of circulating pyrimidine nucleoside to the nucleotide pools of various rat tissues. Most of the uridine entering the circulation (greater than 70%) is catabolized rather than salvaged by formation of nucleotides. Cytidine in the circulation is much more efficiently utilized and is predominantly salvaged. The implication of these results for chemotherapy based on inhibition of pyrimidine synthesis de novo is discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7248957

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  The de novo and salvage pathways for the synthesis of pyrimidine residues of RNA predominate in different locations within the mouse duodenal epithelium.

Authors:  R Bissonnette
Journal:  Cell Tissue Res       Date:  1992-01       Impact factor: 5.249

Review 2.  Pyrimidine metabolism in schistosomes: A comparison with other parasites and the search for potential chemotherapeutic targets.

Authors:  Mahmoud H El Kouni
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  2017-07-21       Impact factor: 2.231

3.  Pyrimidine nucleotide synthesis from exogenous cytidine in the isolated rat heart.

Authors:  S Lortet; J Aussedat; A Rossi
Journal:  Basic Res Cardiol       Date:  1986 May-Jun       Impact factor: 17.165

4.  Pyrimidine metabolism and sugar nucleotide synthesis in rat liver.

Authors:  W R Pels Rijcken; G J Hooghwinkel; W Ferwerda
Journal:  Biochem J       Date:  1990-03-15       Impact factor: 3.857

Review 5.  Physiological concentrations of purines and pyrimidines.

Authors:  T W Traut
Journal:  Mol Cell Biochem       Date:  1994-11-09       Impact factor: 3.396

6.  Pseudouridine and uridine in normal kidney and kidney cancer tissues.

Authors:  K Koshida; J Harmenberg; E Borgström; B Wahren; L Andersson
Journal:  Urol Res       Date:  1985

7.  Comparison of the bioavailability of uridine in mice after either oral or parenteral administration.

Authors:  P Klubes; D B Geffen; R L Cysyk
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.

Authors:  M Markman; T C Chan; S Cleary; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Antibiotic C3368-A, a fungus-derived nucleoside transport inhibitor, potentiates the activity of antitumor drugs.

Authors:  J Su; Y C Zhen; C Q Qi; J L Hu
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites.

Authors:  G J Peters; C J van Groeningen; E J Laurensse; J Lankelma; A Leyva; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.